Center for Rare Movement Disorders Innsbruck, Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Unit for Neuromuscular Disorders and Clinical Neurophysiology, Department of Neurology, Medical University of Innsbruck, 6020 Innsbruck, Austria.
Int J Mol Sci. 2024 Sep 13;25(18):9915. doi: 10.3390/ijms25189915.
Friedreich Ataxia (FRDA) is an inherited neuromuscular disorder triggered by a deficit of the mitochondrial protein frataxin. At a cellular level, frataxin deficiency results in insufficient iron-sulfur cluster biosynthesis and impaired mitochondrial function and adenosine triphosphate production. The main clinical manifestation is a progressive balance and coordination disorder which depends on the involvement of peripheral and central sensory pathways as well as of the cerebellum. Besides the neurological involvement, FRDA affects also the striated muscles. The most prominent manifestation is a hypertrophic cardiomyopathy, which also represents the major determinant of premature mortality. Moreover, FRDA displays skeletal muscle involvement, which contributes to the weakness and marked fatigue evident throughout the course of the disease. Herein, we review skeletal muscle findings in FRDA generated by functional imaging, histology, as well as multiomics techniques in both disease models and in patients. Altogether, these findings corroborate a disease phenotype in skeletal muscle and support the notion of progressive mitochondrial damage as a driver of disease progression in FRDA. Furthermore, we highlight the relevance of skeletal muscle investigations in the development of biomarkers for early-phase trials and future therapeutic strategies in FRDA.
弗里德赖希共济失调(FRDA)是一种遗传性神经肌肉疾病,由线粒体蛋白 frataxin 缺乏引起。在细胞水平上,frataxin 缺乏导致铁硫簇生物合成不足以及线粒体功能和三磷酸腺苷产生受损。主要的临床表现是进行性平衡和协调障碍,这取决于周围和中枢感觉途径以及小脑的参与。除了神经病变外,FRDA 还影响横纹肌。最突出的表现是肥大性心肌病,这也是导致过早死亡的主要决定因素。此外,FRDA 还表现出骨骼肌受累,这导致疾病过程中明显的无力和明显的疲劳。在此,我们通过功能成像、组织学以及疾病模型和患者中的多组学技术,综述了 FRDA 中骨骼肌的发现。总之,这些发现证实了骨骼肌疾病表型,并支持了渐进性线粒体损伤作为 FRDA 疾病进展的驱动因素的观点。此外,我们强调了骨骼肌研究在 FRDA 早期临床试验和未来治疗策略中生物标志物开发中的重要性。